Author

M. A. Al Malki

h-index 42 View on Semantic Scholar

We have 6 of 372 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Graft-versus-host disease prophylaxis shapes T cell biology and immune reconstitution after hematopoietic cell transplant.

Successful hematopoietic cell transplant requires immunosuppression to prevent graft-versus-host disease (GVHD), a lethal, T cell-mediated complication. The phase 3 BMT CTN 1703 trial demonstrated superior GVHD-free/relapse-free survival for posttransplant cyclophosphamide (PT-Cy)-based GVHD prophylaxis versus tacrolim...

S. DeWolf, S. Siegel, Joseph Schmalz et al. · Science Translational Medici... · 0 citations

Open access Oct 2026

Hematopoietic Cell Transplantation Outcomes in the Era of Post-Transplant Cyclophosphamide: Comprehensive Donor Analysis.

It is suggested that PTCy narrows outcome differences across donor types, shifting donor selection from rigid hierarchies and supporting timely HCT using the best available donor.

Y. Aljawai, Masumi Ueda Oshima, Varuna Astha et al. · Blood Advances · 0 citations

Clinical trial Sep 2026

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

BACKGROUND Induction chemotherapy has long been a key component of curative therapy for fit patients with acute myeloid leukemia (AML), despite its frequently severe side effects and substantial health care utilization. For patients who are ineligible for induction chemotherapy, hypomethylating therapy plus venetoclax...

Amir T. Fathi, Alexander E. Perl, Geoffrey Fell et al. · New England Journal of Medic... · 3 citations

Open access Aug 2026

Outcomes after 7/8 and <7/8 mismatched unrelated donor PBSC transplantation with PTCy: results from the ACCESS trial.

Among adult ACCESS recipients treated on a uniform young-donor PBSC/PTCy platform, short-term outcomes with predominantly 6/8 MMUD transplantation were encouraging and should not be interpreted as establishing equivalence with 7/8 MMUD transplantation.

A. J. Jimenez Jimenez, Joseph Stanek, Brent Logan et al. · Blood Advances · 0 citations

Open access Aug 2026

Phase II Study of Posttransplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After HLA-Mismatched Unrelated Donor Reduced Intensity Transplantation: Results From the ACCESS Trial Expansion Cohort.

MMUD with PTCy-based GVHD prophylaxis and RIC/NMA conditioning was safe and effective to facilitate HCT and outcomes were similar in the expansion cohort that enrolled from a greater number of centers.

Brian C. Shaffer, M. A. Al Malki, Antonio M. Jimenez et al. · American journal of hematolo... · 0 citations

Open access Aug 2026

Pegtarazimod limits acute graft-versus-host disease mortality and severity in mice and is tolerated in patients.

Pegtarazimod reduced aGVHD in mice by suppressing pro inflammatory neutrophil effector functions and preserving enterocyte integrity and the clinical trial data support tolerability of pegtarazimod in aGVHD patients and further studies are needed to determine efficacy.

Verena Holzmüller, Jana Gawron, Ann-Cathrin Burk et al. · Journal of Clinical Investig... · 0 citations